metoclopramide has been researched along with Abnormalities, Drug-Induced in 8 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 8.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Metoclopramide use in pregnancy was not associated with increased risk of major congenital malformations overall, any of the 20 individual malformation categories assessed, spontaneous abortion, or stillbirth." | 7.79 | Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. ( Hviid, A; Melbye, M; Mølgaard-Nielsen, D; Pasternak, B; Svanström, H, 2013) |
| "In various countries, metoclopramide is the antiemetic drug of choice in pregnant women, but insufficient information exists regarding its safety in pregnancy." | 7.75 | The safety of metoclopramide use in the first trimester of pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Sheiner, E; Wiznitzer, A, 2009) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 4.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM." | 3.91 | New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019) |
| "Metoclopramide use in pregnancy was not associated with increased risk of major congenital malformations overall, any of the 20 individual malformation categories assessed, spontaneous abortion, or stillbirth." | 3.79 | Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. ( Hviid, A; Melbye, M; Mølgaard-Nielsen, D; Pasternak, B; Svanström, H, 2013) |
| "In various countries, metoclopramide is the antiemetic drug of choice in pregnant women, but insufficient information exists regarding its safety in pregnancy." | 3.75 | The safety of metoclopramide use in the first trimester of pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Sheiner, E; Wiznitzer, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sakran, R | 1 |
| Shechtman, S | 1 |
| Arnon, J | 1 |
| Diav-Citrin, O | 1 |
| Bérard, A | 1 |
| Sheehy, O | 1 |
| Gorgui, J | 1 |
| Zhao, JP | 1 |
| Soares de Moura, C | 1 |
| Bernatsky, S | 1 |
| Pasternak, B | 2 |
| Svanström, H | 2 |
| Mølgaard-Nielsen, D | 1 |
| Melbye, M | 1 |
| Hviid, A | 2 |
| Matok, I | 2 |
| Perlman, A | 1 |
| Vrachnis, N | 1 |
| Zygouris, D | 1 |
| Iliodromiti, Z | 1 |
| Tan, PC | 1 |
| Gorodischer, R | 1 |
| Koren, G | 1 |
| Sheiner, E | 1 |
| Wiznitzer, A | 1 |
| Levy, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for metoclopramide and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
Metoclopramide in pregnancy and risk of major congenital malformations and fetal death.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antiemetics; Case-Control Studies; Denmar | 2013 |
Metoclopramide in pregnancy: no association with adverse fetal and neonatal outcomes.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Fetal Death; Humans; Metoclopramide; Pregnancy | 2014 |
Fetal outcomes associated with metoclopramide use in pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Fetal Death; Humans; Metoclopramide; Pregnancy | 2014 |
Fetal outcomes associated with metoclopramide use in pregnancy--reply.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Fetal Death; Humans; Metoclopramide; Pregnancy | 2014 |
ACP Journal Club. Metoclopramide during pregnancy did not increase risk for major congenital malformations or fetal death.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Fetal Death; Humans; Metoclopramide; Pregnancy | 2014 |
The safety of metoclopramide use in the first trimester of pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cohort Studies; Female; Fetus; Humans; Infant, Low Birth W | 2009 |